Ambry Genetics

Ambry Genetics is a leading, well-established clinical genetic testing laboratory with a 25-year history. Its core business focuses on diagnostic services for hereditary cancer and rare diseases, leveraging proprietary technologies like +RNAinsight™ and the Patient for Life™ reanalysis program to improve diagnostic yield and accuracy. The company operates a services-based business model, generating revenue from test fees, and has processed over one million tests, demonstrating significant market adoption. Ambry emphasizes scientific rigor, participates in landmark research, and offers digital health tools like the Ambry CARE Program® to identify at-risk patients.

Integrated DNA and RNA analysis platform (+RNAinsight®) for variant detection and classification; Proactive exome reanalysis (Patient for Life™); Digital health platform for patient identification (CARE Program®).

Ambry competes in the crowded clinical genetic testing market against large public diagnostics companies (e.g., Labcorp, Quest, Myriad Genetics) and other specialized labs. Its differentiation is based on scientific rigor, proprietary RNA-informed testing, and unique service models like lifelong exome reanalysis, rather than competing solely on price or test menu breadth.